Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group
Aim. To analyze the results of allogeneic and autologous hemopoietic cell transplantations (allo- and auto-HCT) in children with acute myeloid leukemia (AML) from an intermediate risk group, most of which were performed using lower-intensity conditioning modes. Subjects and methods. The study enroll...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2010-07-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/30616 |
| _version_ | 1818339640334090240 |
|---|---|
| author | Z M Dyshlevaya E V Skorobogatova M A Maschan I P Shipitsyna Yu V Skvortsova P E Trakhtman D N Balashov Yu V Pashko E E Kurnikova E V Suntsova O V Goronkova G G Solopova D D Baidildina I I Kalinina L A Khachatryan M M Shneider A A Maschan |
| author_facet | Z M Dyshlevaya E V Skorobogatova M A Maschan I P Shipitsyna Yu V Skvortsova P E Trakhtman D N Balashov Yu V Pashko E E Kurnikova E V Suntsova O V Goronkova G G Solopova D D Baidildina I I Kalinina L A Khachatryan M M Shneider A A Maschan |
| author_sort | Z M Dyshlevaya |
| collection | DOAJ |
| description | Aim. To analyze the results of allogeneic and autologous hemopoietic cell transplantations (allo- and auto-HCT) in children with acute myeloid leukemia (AML) from an intermediate risk group, most of which were performed using lower-intensity conditioning modes.
Subjects and methods. The study enrolled 36 children from an intermediate risk group, who had undergone auto-HCT (n = 22) or allo-HCT (n = 14) in December 1994 to December 2008. The patients' age was 0.7 to 16.6 years (median 12.8 years). Chemotherapeutic conditioning regimens were applied to all the patients. Melphalan was a basic myeloablative agent in 83.3% of cases.
Results. With a median follow-up of 4.6 years (1.1-13.8 years), three-year relapse-free survival (RFS) was 80.4%; overall survival (OS) was 65.6%. Recurrences were documented only in 6 (16.6%) patients from the auto-HCT. Transplantation-associated mortality (TAM) was 13.8% (five patients died). After allo-HCT versus auto-HCT, RFS, OS, and TAM were 100 and 68.7% (p = 0.03), 93.2 and 55.5% (p = 0.02), and 7.1 and 18.2%, respectively. Acute and chronic graft-versus-host reactions developed in 57.1 and 23.1%, respectively.
Conclusion. Transplantation of allogeneic hemopoietic cells from a compatible related donor in the intermediate risk group children with AML, by using melphalan-based conditioning regimen, demonstrates a high survival rate with the minimum toxicity. |
| first_indexed | 2024-12-13T15:30:13Z |
| format | Article |
| id | doaj.art-10dd86ccbaa341b7856c227fcea1b525 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-13T15:30:13Z |
| publishDate | 2010-07-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-10dd86ccbaa341b7856c227fcea1b5252022-12-21T23:40:13Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422010-07-01827344027644Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk groupZ M Dyshlevaya0E V Skorobogatova1M A Maschan2I P Shipitsyna3Yu V Skvortsova4P E Trakhtman5D N Balashov6Yu V Pashko7E E Kurnikova8E V Suntsova9O V Goronkova10G G Solopova11D D Baidildina12I I Kalinina13L A Khachatryan14M M Shneider15A A Maschan16Russian Children's Hospital, MoscowRussian Children's Hospital, MoscowFederal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian FederationRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowRussian Children's Hospital, MoscowFederal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian FederationFederal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian FederationAim. To analyze the results of allogeneic and autologous hemopoietic cell transplantations (allo- and auto-HCT) in children with acute myeloid leukemia (AML) from an intermediate risk group, most of which were performed using lower-intensity conditioning modes. Subjects and methods. The study enrolled 36 children from an intermediate risk group, who had undergone auto-HCT (n = 22) or allo-HCT (n = 14) in December 1994 to December 2008. The patients' age was 0.7 to 16.6 years (median 12.8 years). Chemotherapeutic conditioning regimens were applied to all the patients. Melphalan was a basic myeloablative agent in 83.3% of cases. Results. With a median follow-up of 4.6 years (1.1-13.8 years), three-year relapse-free survival (RFS) was 80.4%; overall survival (OS) was 65.6%. Recurrences were documented only in 6 (16.6%) patients from the auto-HCT. Transplantation-associated mortality (TAM) was 13.8% (five patients died). After allo-HCT versus auto-HCT, RFS, OS, and TAM were 100 and 68.7% (p = 0.03), 93.2 and 55.5% (p = 0.02), and 7.1 and 18.2%, respectively. Acute and chronic graft-versus-host reactions developed in 57.1 and 23.1%, respectively. Conclusion. Transplantation of allogeneic hemopoietic cells from a compatible related donor in the intermediate risk group children with AML, by using melphalan-based conditioning regimen, demonstrates a high survival rate with the minimum toxicity.https://ter-arkhiv.ru/0040-3660/article/view/30616acute myeloid leukemiachildrenhemopoietic cell transplantationstreatmentefficiencysurvivalmelphalan |
| spellingShingle | Z M Dyshlevaya E V Skorobogatova M A Maschan I P Shipitsyna Yu V Skvortsova P E Trakhtman D N Balashov Yu V Pashko E E Kurnikova E V Suntsova O V Goronkova G G Solopova D D Baidildina I I Kalinina L A Khachatryan M M Shneider A A Maschan Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group Терапевтический архив acute myeloid leukemia children hemopoietic cell transplantations treatment efficiency survival melphalan |
| title | Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| title_full | Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| title_fullStr | Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| title_full_unstemmed | Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| title_short | Results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| title_sort | results of hemopoietic cell transplantation in the first complete remission in children with acute myeloid leukemia from an intermediate risk group |
| topic | acute myeloid leukemia children hemopoietic cell transplantations treatment efficiency survival melphalan |
| url | https://ter-arkhiv.ru/0040-3660/article/view/30616 |
| work_keys_str_mv | AT zmdyshlevaya resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT evskorobogatova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT mamaschan resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT ipshipitsyna resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT yuvskvortsova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT petrakhtman resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT dnbalashov resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT yuvpashko resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT eekurnikova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT evsuntsova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT ovgoronkova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT ggsolopova resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT ddbaidildina resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT iikalinina resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT lakhachatryan resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT mmshneider resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup AT aamaschan resultsofhemopoieticcelltransplantationinthefirstcompleteremissioninchildrenwithacutemyeloidleukemiafromanintermediateriskgroup |